Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.

Autor:	Ranjan T; Department of Neuro-Oncology, Allegheny Health Network, Pittsburgh, PA, USA; Department of Neuro-Oncology, Cancer Center Southern Florida, Tampa General Hospital, Tampa, FL, USA., Sengupta S; Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA., Glantz MJ; Department of Neurosurgery, Penn State Neuroscience Institute, Hershey, PA, USA., Green RM; Department of Neuro-Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA., Yu A; Department of Neurosurgery, Allegheny Health Network, Pittsburgh, PA, USA., Aregawi D; Department of Neurosurgery, Penn State Neuroscience Institute, Hershey, PA, USA., Chaudhary R; Department of Internal Medicine, Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA., Chen R; Department of Neuro-Oncology, Providence Brain & Spine Institute, Portland, OR, USA., Zuccarello M; Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA., Lu-Emerson C; Department of Neuro-Oncology, Maine Medical Center, Scarborough, ME, USA., Moulding HD; Department of Neuroscience, St. Luke's University Hospital & Health Network, Bethlehem, PA, USA., Belman N; Department of Neuroscience, St. Luke's University Hospital & Health Network, Bethlehem, PA, USA., Glass J; Departments of Neurology and Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA., Mammoser A; Department of Neurosurgery, LSU Health Sciences Center, New Orleans, LA, USA., Anderson M; Department of Neurology, University of Mississippi Medical Center, Jackson, MS, USA., Valluri J; Cordgenics, LLC, Huntington WV, USA., Marko N; Department of Neurosurgery, LewisGale Regional Health System, Salem, VA, USA., Schroeder J; Department of Neurosurgery, University of Toledo, Toledo, OH, USA., Jubelirer S; Department of Neuro-Oncology, Charleston Area Medical Center, Charleston, WV, USA., Chow F; Departments of Neurological Surgery and Neurology, University of Southern California, Los Angeles, CA, USA., Claudio PP; Cordgenics, LLC, Huntington WV, USA; Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS, USA., Alberico AM; Department of Neurosurgery, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA., Lirette ST; Department of Data Science, University of Mississippi Medical Center, Jackson, MS, USA., Denning KL; Department of Pathology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA., Howard CM; Department of Radiology, University of Mississippi Medical Center, Jackson, MS, USA. Electronic address: cmhoward@umc.edu.
Jazyk:	angličtina
Zdroj:	Cell reports. Medicine [Cell Rep Med] 2023 May 16; Vol. 4 (5), pp. 101025. Date of Electronic Publication: 2023 May 02.
DOI:	10.1016/j.xcrm.2023.101025
Abstrakt:	Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2-14.7) compared with 9 months (95% CI, 4.2-13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24-0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world. Competing Interests: Declaration of interests P.P.C. and J.V. report ownership of intellectual property rights on the CSC platform technology licensed to Cordgenics, LLC. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu